Table 2.
Control | hGal | hGal AL1576 |
hGal Tolrestat |
hGal SDI |
hGal Mannitol |
|
---|---|---|---|---|---|---|
Galactitol | 0# | 90.3 ± 3.2 | 1.2 ± .3# | 27.3 ± 1.4# | 89.4 ± 2.9 | 87.7 ± 3.7 |
bFGF | 0.61 ± 0.06 | 0.84 ±0.01* | 0.70 ± 0.02 | 0.71 ± 0.06 | 0.81 ± 0.03* | 0.68 ± 0.04 |
TGF-β | 0.68 ± 0.16 | 0.90 ± 0.12* | 0.75 ± 0.02 | 0.69 ± 0.02 | 0.93 ± 0.07 | 0.79 ± 0.04 |
p-SAPK/JNK | 0.62 ± 0.08 | 0.84 ± 0.02* | 0.66 ± 0.06 | 0.57 ± 0.09 | 0.84 ± 0.02* | 0.72 ± 0.04 |
p-ERK 1/2 | 0.67 ±0.06 | 0.96 ± 0.02* | 0.76 ± 0.05 | 0.69 ± 0.04 | 0.94 ± 0.02* | 0.72 ± 0.10 |
p-Akt | 0.54 ± 0.05 | 0.89 ± 0.13* | 0.67 ± 0.05 | 0.63 ± 0.02 | 0.81 ± 0.04* | 0.65 ± 0.10 |
significantly different (p ≤ 0.05) from the untreated hGal group or
significantly different (p ≤ 0.05) from control group.